Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Maxim Group analyst Jason McCarthy maintained a Hold rating on Vertex Pharmaceuticals (VRTXResearch Report) today. The company’s shares closed last Thursday at $251.20.

According to, McCarthy is a 4-star analyst with an average return of 5.3% and a 36.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, SELLAS Life Sciences Group, and Actinium Pharmaceuticals.

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $285.06, which is a 10.6% upside from current levels. In a report issued on April 28, RBC Capital also downgraded the stock to Hold with a $260.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $277.80 and a one-year low of $164.08. Currently, Vertex Pharmaceuticals has an average volume of 2.18M.

Based on the recent corporate insider activity of 154 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VRTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.